与仿真抗原受体T细胞疗法相关的血液和淋巴系统疾病:FDA不良事件报告系统 (FAERS) 数据库的药监测分析
Zhenpo Zhang1, Jingping Zheng1, Yankun Liang1
1College of Pharmacy, Jinan University, Guangzhou, Guangdong, China.
BMC cancer
|May 9, 2025
概括
血液和淋巴不良事件 (AE) 是化学抗原受体T细胞 (CAR-T) 治疗中的重大挑战. 这项研究确定了关键的副作用,包括B细胞无形成症和细胞衰退,并发现脏出血,DIC和全细胞衰退与CAR-T患者的死亡率高度相关.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 药物监督 药物监督 药物监督
背景情况:
- 化学抗原受体T细胞 (CAR-T) 疗法越来越多地用于癌症治疗.
- 血液和淋巴不良事件 (AEs) 带来了重大的临床挑战.
- 需要对与CAR-T相关的血液学和淋巴学AE进行全面的调查.
研究的目的:
- 综合调查和总结与CAR-T疗法相关的血液和淋巴性副作用.
- 通过不成比例性分析识别与CAR-T治疗相关的特定副作用.
- 为了确定与CAR-T患者的死亡率相关的血液和淋巴性副作用.
主要方法:
- 从FDA不良事件报告系统 (FAERS) 数据库 (2017年8月 - 2023年12月) 提取了与CAR-T相关的不良事件报告.
- 使用不成比例分析 (报告赔率比率[ROR]和信息组件[IC]) 来识别重要的AE.
- 采用LASSO回归分析来识别与死亡相关的血液和淋巴性副作用.
主要成果:
- 在FAERS数据库中确定了1600种血液和淋巴的副作用;15.3%的病例导致了致命的结果.
- 检测到25个显著的AE信号,其中B细胞无形成,细胞衰减和低纤维素生成血是突出的.
- 观察到大多数AE发生在输液后10天内;脏出血,DIC和泛细胞衰竭与死亡率高度相关.
结论:
- 血液和淋巴性AE与抗CD19的CAR-T和含CD28的CAR-T疗法更密切相关.
- 脏出血,扩散性血管内凝血 (DIC) 和全细胞衰竭是与死亡率增加相关的关键性副作用.
- 这些严重的副作用虽然较少报告,但在接受CAR-T治疗的患者中需要密切的临床监测.
更多相关视频
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
1.2K
06:18Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
Published on: August 18, 2023
2.3K
相关概念视频
01:19Pharmacovigilance
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
01:26Therapeutic Drug Monitoring: Drug Analysis Methods
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...